L’ACMTS tient à appuyer les décideurs du secteur de la santé canadiens durant cette période difficile et incertaine.
Pour trouver des outils, ressources et données probantes touchant la COVID-19, consultez notre portail sur la COVID-19.


Begin main content
Date: 29 mars 2012
Type de résultat : Ressources

(Contenu en anglais seulement)

The Canadian Agency for Drugs and Technologies in Health (CADTH), with input from the Medical Isotopes and Imaging Modalities Advisory Committee (MIIMAC), has developed the S.M.A.R.T. tool. This practical tool will provide your organization with an interactive and customizable application that helps you to prioritize the use of technetium-99m (99mTc)-based imaging procedures in the event of a disruption in the supply of the isotope. The S.M.A.R.T. tool uses a multi-criteria decision analysis (MCDA)-based approach to prioritize 24 of the most common clinical uses of 99mTc-based imaging, based on 11 evaluative criteria. MIIMAC developed the criteria after extensive discussion and deliberation, taking into consideration traditional clinical factors, as well as patient-focused factors, in order to ensure that health benefits were defined from multiple relevant perspectives. For a more detailed explanation of the methodology used, please see the final report.

The S.M.A.R.T. tool will provide your organization with:

  • A customized priority list of up to 24 clinical uses of 99mTc-based imaging, which can be referred to during a supply disruption.
  • A priority list of alternative diagnostic imaging modalities for each clinical use that can be used in lieu of 99mTc-based imaging.


Launch "S.M.A.R.T." Tool